Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Achillion Pharmaceuticals (ACHN) Stock Price
Media headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5647745339359 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Achillion Pharma (ACHN) Announces Paul Firuta as COO (streetinsider.com)
- Achillion appoints Paul Firuta as Chief Operating Officer (seekingalpha.com)
- Achillion Appoints Paul Firuta Chief Operating Officer (finance.yahoo.com)
- Why Is Achillion (ACHN) Up 24.7% Since Last Earnings Report? (finance.yahoo.com)
- Analysts Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.14 Earnings Per Share (americanbankingnews.com)
NASDAQ:ACHN traded down $0.01 during trading hours on Monday, hitting $3.27. The company’s stock had a trading volume of 18,648 shares, compared to its average volume of 1,267,839. The firm has a market capitalization of $453.18 million, a PE ratio of -5.27 and a beta of 1.01. Achillion Pharmaceuticals has a 52-week low of $2.33 and a 52-week high of $5.00.
A number of analysts have recently weighed in on ACHN shares. Barclays raised Achillion Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $5.00 price objective on the stock in a research report on Monday, May 21st. ValuEngine raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 29th. Finally, BidaskClub lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $4.67.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Further Reading: Penny Stocks, What You Need To Know
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.